Vertex Pharmaceuticals (VRTX) Q1 2026 Financial Results Summary

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) released its consolidated financial results for the first quarter ended March 31, 2026, on April 29, 2026. Below is a summary of the key financial and operational highlights from the report.

Financial Highlights

• Total Revenue:
  • $2.99 billion, an 8% increase compared to Q1 2025 ($2.77 billion).
    • U.S. revenue increased by 7% to $1.78 billion.
    • International revenue grew by 9% to $1.21 billion.
• Operating Expenses:
  • Combined GAAP and non-GAAP Research & Development, Acquired IPR&D, and SG&A expenses were $1.5 billion, compared to $1.4 billion for Q1 2025.
    • R&D expenses were $961.6 million (down from $979.7 million).
    • SG&A expenses increased to $493.7 million from $396.4 million.
• Effective Tax Rate:
  • GAAP effective tax rate for Q1 2026 was 17.7%, an increase from 11.5% in Q1 2025.
  • Non-GAAP effective tax rate was 19.6%, compared to 18.8% a year ago.
• Net Income:
  • GAAP net income was $1.0 billion versus $646 million in Q1 2025.
  • Non-GAAP net income was $1.1 billion, an increase of $93 million from Q1 2025.
• Cash and Cash Equivalents:
  • $13.0 billion as of March 31, 2026, compared to $12.3 billion at the end of 2025, primarily due to cash flows from operating activities.

Share Repurchase Program

Vertex has engaged in repurchases of its common stock as part of its ongoing share repurchase programs.

Financial Guidance for Full Year 2026

• Total Revenue:
  • Guidance remains $12.95 billion to $13.1 billion, with expectations of over $500 million from non-CF products.
• Expenses:
  • Combined GAAP and non-GAAP R&D, IPR&D, and SG&A expenses are maintained at $6.3 to $6.45 billion.
• Effective Tax Rate:
  • Non-GAAP effective tax rate guidance remains unchanged at 19.5% to 20.5%.

Business Highlights

• Cystic Fibrosis (CF) Portfolio:
  • Vertex's CF therapies continue to perform strongly; ALYFTREK and TRIKAFTA have recently seen label expansions, affecting 95% of CF patients.
  • ALYFTREK generated $424.4 million in Q1 2026, up from $53.9 million in Q1 2025.
• CASGEVY:
  • Revenue from CASGEVY was $42.9 million, a significant increase from $14.2 million.
  • The FDA has expedited the approval process for CASGEVY in children ages 5 to under 12 years old.
• JOURNAVX:
  • Revenue reached $29 million in Q1 2026, up from $1.3 million in Q1 2025.
  • Over 1 million prescriptions have been filled since its launch in March 2025.
• Povetacicept Program:
  • Continued advancements in the development of POVETACICEPT aimed at treating multiple diseases, including IgA nephropathy.

R&D Pipeline Progress

Vertex is enhancing its pipeline with new studies and product development focused on diseases such as IgA nephropathy, sickle cell disease, and myotonic dystrophy type 1. Positive interim analysis for the povetacicept Phase 3 trial and ongoing studies in diabetic peripheral neuropathy are highlighted.

Conclusion

Vertex Pharmaceuticals has demonstrated robust growth in its financial results for Q1 2026, fueled by strong sales in cystic fibrosis therapies and the diversification of its product line. The company is also continuing to execute its strategic plans and advance pipeline programs for significant long-term value creation.

For further details, refer to Vertex's investor communications or visit their official website.

Note: All amounts are in millions.

Revenues:	March 31, 2026	March 31, 2025
Product revenues, net	$2,986.9	$2,760.2
Other revenues	—	10.0
Total revenues	2,986.9	2,770.2
Costs and expenses:
Cost of sales	392.8	363.0
Research and development expenses	961.6	979.7
Acquired in-process research and development expenses	0.5	19.8
Selling, general and administrative expenses	493.7	396.4
Intangible asset impairment charge	—	379.0
Change in fair value of contingent consideration	0.2	2.2
Total costs and expenses	1,848.8	2,140.1
Income from operations	1,138.1	630.1
Interest income, net	114.8	117.9
Other expense, net	—	-17.6
Income before provision for income taxes	1,252.9	730.4
Provision for income taxes	221.5	84.1
Net income	$1,031.4	$646.3
Net income per common share:
Basic	$4.06	$2.52
Diluted	$4.02	$2.49
Shares used in per share calculations:
Basic	254.1	256.9
Diluted	256.3	259.5

Note: All amounts are in millions.

	March 31, 2026	December 31, 2025
Assets
Cash, cash equivalents and marketable securities	$7,246.7	$6,608.1
Accounts receivable, net	1,996.1	2,052.8
Inventories	1,766.7	1,686.8
Prepaid expenses and other current assets	720.8	853.3
Total current assets	11,730.3	11,201.0
Property and equipment, net	1,608.4	1,520.3
Goodwill and other intangible assets, net	1,506.5	1,512.2
Deferred tax assets	2,947.8	2,897.9
Operating lease assets	1,685.1	1,562.7
Long-term marketable securities	5,749.9	5,712.3
Other long-term assets	1,256.4	1,236.6
Total assets	$26,484.4	$25,643.0
Liabilities and Shareholders' Equity
Accounts payable and accrued expenses	$3,473.5	$3,432.9
Other current liabilities	407.1	428.3
Total current liabilities	3,880.6	3,861.2
Long-term operating lease liabilities	1,986.5	1,846.5
Other long-term liabilities	1,255.4	1,269.5
Shareholders' equity	19,361.9	18,665.8
Total liabilities and shareholders' equity	$26,484.4	$25,643.0
Common shares outstanding	254.2	254.0

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.